Skip to content
Back to CLYM

Climb Bio, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
9
Purchases
3
Sales
6
Purchase value
$779.63K
Sale value
$2.65M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Stephen Basil ThomasDirector
4Rule 10b5-1 plan disclosed
Filed Sep 17, 2026Period of report Sep 15, 20260001193125-26-394357
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 15, 2026
Common StockF1F2F3100,000$13.6682$1.37M467,969Direct
Filing footnotes · 3
  1. F1These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2026.
  2. F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.3800 to $14.3400, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. F3Includes 413,312 shares of the issuer's common stock, par value $0.0001 per share, distributed by Sera Medicines, LLC to certain of its limited partners, including the reporting person, for no consideration in a pro-rata in-kind distribution.
Open on SEC EDGAR
Aoife BrennanDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Jun 30, 2026Period of report Jun 27, 20260001193125-26-291131
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 29, 2026
Common StockF3F430,902$13.17$406.98K87,731Direct
Filing footnotes · 6
  1. F1Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock
  2. F2Total includes an additional 1,751 shares acquired through the Company's Employee Stock Purchase Plan.
  3. F3The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs.
  4. F4The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.02 to $13.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  5. F5Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
  6. F6The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service.
Open on SEC EDGAR
Stephen Basil ThomasDirector
4Rule 10b5-1 plan disclosed
Filed Feb 27, 2026Period of report Feb 25, 20260001193125-26-082533
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 26, 2026
Common StockF1F316,313$7.006$114.29K154,657Direct
SaleFeb 25, 2026
Common StockF1F233,687$7.0046$235.96K170,970Direct
Filing footnotes · 3
  1. F1These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 14, 2025.
  2. F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.0000 to $7.0600, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4.
  3. F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.0000 to $7.0400, inclusive.
Open on SEC EDGAR
Stephen Basil ThomasDirector
4Rule 10b5-1 plan disclosed
Filed Feb 17, 2026Period of report Feb 12, 20260001193125-26-054568
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 13, 2026
Common StockF1F310,000$5.8141$58.14K204,657Direct
SaleFeb 12, 2026
Common StockF1F290,000$5.2332$470.99K214,657Direct
Filing footnotes · 3
  1. F1These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 14, 2025.
  2. F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.2212 to $5.2481, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4.
  3. F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.6200 to $6.1200, inclusive.
Open on SEC EDGAR
Peter KolchinskyDirector · 10% owner
Capital Healthcare Fund LP RADirector · 10% owner
L.P. RA Capital ManagementDirector · 10% owner
L.P. RA Capital Nexus Fund IIIDirector · 10% owner
L.P. RA Capital Nexus Fund IIDirector
L.P. RA Capital Nexus FundDirector
Rajeev M. ShahDirector · 10% owner
4
Filed Jan 7, 2026Period of report Jan 5, 20260001231919-26-000018
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseJan 5, 2026
Common StockF1F2F37,111$3.50$24.89K3,403,429IndirectSee footnotes
Filing footnotes · 8
  1. F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.495 to $3.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  2. F2These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
  3. F3RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 75% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.
  4. F4These securities are held directly by Sera.
  5. F5These securities are held directly by the Nexus Fund.
  6. F6These securities are held directly by the Nexus Fund II.
  7. F7These securities are held directly by Nexus Fund III.
  8. F8These securities are held directly by the Account.
Open on SEC EDGAR
Peter KolchinskyDirector · 10% owner
Capital Healthcare Fund LP RADirector · 10% owner
L.P. RA Capital ManagementDirector · 10% owner
L.P. RA Capital Nexus Fund IIIDirector · 10% owner
L.P. RA Capital Nexus Fund IIDirector
L.P. RA Capital Nexus FundDirector
Rajeev M. ShahDirector · 10% owner
4
Filed Dec 15, 2025Period of report Dec 11, 20250001231919-25-000616
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseDec 12, 2025
Common StockF5F2F3101,462$2.86$290.18K3,396,318IndirectSee footnotes
PurchaseDec 11, 2025
Common StockF4F2F3213,099$2.18$464.56K3,294,856IndirectSee footnotes
Filing footnotes · 11
  1. F1On December 11, 2025, RA Capital Healthcare Fund, L.P. (the "Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 20,440,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 20,440,000 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share.
  2. F10These securities are held directly by the Account.
  3. F11The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 33.0% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.
  4. F2These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
  5. F3RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 75% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.
  6. F4The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.11 to $2.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  7. F5The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.32 to $3.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  8. F6These securities are held directly by Sera.
  9. F7These securities are held directly by the Nexus Fund.
  10. F8These securities are held directly by the Nexus Fund II.
  11. F9These securities are held directly by Nexus Fund III.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.